PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pharming Group N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026
$9.11−0.25 (-2.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 2277.5
- Dividend yield
- –
Share price
−$4.89 (−34.93%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Pharming Group N.V. grew revenue 26.6% to $376.13M over fiscal 2025. Free cash flow was $53.96M.
Revenue
$376.13M
+26.6% vs. a year earlier
Operating income
$25.84M
FY2025
Free cash flow
$53.96M
FY2025
EPS, diluted
$0.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 2277.5
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $376.13M
- Net income
- $2.85M
- EPS, diluted
- $0.00
- Free cash flow
- $53.96M
Eight years at a glance
Fiscal years 2018 to 2025, USD
Revenue
$376.13M+26.6% YoY
Gross profit
$330.63M+26.3% YoY
Operating income
$25.84M
Net income
$2.85M
EPS, diluted
$0.00
Free cash flow
$53.96M
Reported period